Towards climate-neutral aviation: Assessment of maintenance requirements for airborne hydrogen storage and distribution systems

Airlines are faced with the challenge of reducing their environmental footprint in an effort to push for climate-neutral initiatives that comply with international regulations. In the past, the aviation industry has followed the approach of incremental improvement of fuel efficiency while simultaneously experiencing significant growth in annual air traffic. With the increase in air traffic negating any reduction in Greenhouse Gas (GHG) emissions, more disruptive technologies such as hydrogen-based onboard power generation are required to reduce the environmental impact of airline operations. However, despite initial euphoria and first conceptual studies for hydrogen-powered aircraft several decades ago, there still has been no mass adoption to this day. Besides the challenges of a suitable ground infrastructure, this can partly be attributed to uncertainties with the associated maintenance requirements and the expected operating costs to demonstrate the economic viability of this technology. With this study, we address this knowledge gap by estimating changes towards scheduled maintenance activities for an airborne hydrogen storage and distribution system. In particular, we develop a detailed system design for a hydrogen-powered, fuel-cell-based auxiliary power generation and perform a comparative analysis with an Airbus A320 legacy system. That analysis allows us to (a) identify changes for the expected maintenance effort to enhance subsequent techno-economic assessments, (b) identify implications of specific design assumptions with corresponding maintenance activities while ensuring regulatory compliance and (c) describe the impact on the resulting task execution. The thoroughly examined interactions between system design and subsequent maintenance requirements of this study can support practitioners in the development of prospective hydrogen-powered aircraft. In particular, it allows the inclusion of maintenance implications in early design stages of corresponding system architectures. Furthermore, since the presented methodology is transferable to different design solutions, it provides a blueprint for alternative operating concepts such as the complete substitution of kerosene by hydrogen to power the main engines

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

BACKGROUND: The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in (18 )F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes. METHODS/DESIGN: The REMOTUX trial is an investigator-initiated, prospective, open-label, single-arm, single-center early exploratory predictive study. The first (18 )F-FDG PET-CT is conducted at baseline followed by the run-in phase with cetuximab at days 1 and 8. At day 14, the second (18 )F-FDG PET-CT is performed. Subsequently, patients are treated according to the Folfiri-cetuximab regimen as an active and approved first-line regimen for metastatic colorectal carcinoma. At day 56, clinical response is evaluated with a CT-scan compared to the baseline analysis. Tracer uptake is assessed using standardized uptake values (SUVs). The main hypothesis to be tested in the primary analysis is whether or not the relative change in the SUV from baseline to day 14 has any predictive relevance for early clinical response determined at day 56. Patients are followed until death from any cause or until 24 months after the last patient has ended trial treatment. DISCUSSION: The aim of this trial is to evaluate metabolic changes in metastatic colorectal cancer during short-term single agent treatment with cetuximab and to analyse their potential of predicting early clinical response. This could be helpful to answer the question if early identification of patients not responding to cetuximab is possible. TRIAL REGISTRATION: ClinicalTrials.gov NCT200811021020; EudraCT 20090132792

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients

Background: To prove the feasibility of integrating CT urography (CTU) into 68Ga-PSMA-11 PET/CT and to analyze the impact of CTU on assigning focal tracer accumulation in the ureteric space to either ureteric excretion or metastatic disease concerning topographic attribution and diagnostic confidence. Methods: Ten prostate cancer patients who underwent 68Ga-PSMA-11 PET/CT including CTU because of biochemical relapse or known metastatic disease were retrospectively analyzed. CTU consisted of an excretory phase 10 min after injection of 80 mL iodinated contrast material. Ureter opacification at CTU was evaluated using the following score: 0, 0% opacification; 1, < 50%; 2, 50–99%; 3, 100%. Topographic attribution and confidence of topographic attribution of focal tracer accumulation in the ureteric space were separately assessed for 68Ga-PSMA-11 PET/CT without and with CTU. Diagnostic confidence was evaluated using the following score: 0, < 25% confidence; 1, 26–50%; 2, 51–75%; 3, 76–100%. Results: At CTU, mean ureter opacification score was 2.6 ± 0.7. At 68Ga-PSMA-11 PET/CT without CTU, mean confidence of topographic attribution of focal tracer accumulation was 2.5 ± 0.7 in total and 2.6 ± 0.7 for metastatic disease. At 68Ga-PSMA-11 PET/CT with CTU, mean confidence of topographic attribution of focal areas of tracer accumulation was significantly higher with 2.9 ± 0.2 in total and 2.7 ± 0.9 for metastatic disease (p < 0.001). In 4 of 34 findings (12%) attribution to either ureteric excretion or metastatic disease was discrepant between 68Ga-PSMA-11 PET/CT without and with CTU (n.s). Conclusions: Integration of CTU into 68Ga-PSMA-11 PET/CT is feasible and increases diagnostic confidence of assigning focal areas of tracer accumulation in the ureteric space to either metastatic disease or ureteric excretion

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

PURPOSE : FAPI ligands (fibroblast activation protein inhibitor), a novel class of radiotracers for PET/CT imaging, demonstrated in previous studies rapid and high tumor uptake. The purpose of this study is the head-to-head intra-individual comparison of 68Ga- FAPI versus standard-of-care 18F-FDG in PET/CT in organ biodistribution and tumor uptake in patients with various cancers. MARERILA AND METHODS : This international retrospective multicenter analysis included PET/CT data from 71 patients from 6 centers who underwent both 68Ga-FAPI and 18F-FDG PET/CT within a median time interval of 10 days (range 1–89 days). Volumes of interest (VOIs) were manually drawn in normal organs and tumor lesions to quantify tracer uptake by SUVmax and SUVmean. Furthermore, tumor-to-background ratios (TBR) were generated (SUVmax tumor/ SUVmax organ). RESULTS : A total of 71 patients were studied of, which 28 were female and 43 male (median age 60). In 41 of 71 patients, the primary tumor was present. Forty-three of 71 patients exhibited 162 metastatic lesions. 68Ga-FAPI uptake in primary tumors and metastases was comparable to 18F-FDG in most cases. The SUVmax was significantly lower for 68Ga-FAPI than 18F-FDG in background tissues such as the brain, oral mucosa, myocardium, blood pool, liver, pancreas, and colon. Thus, 68Ga-FAPI TBRs were significantly higher than 18F-FDG TBRs in some sites, including liver and bone metastases. CONCLUSION : Quantitative tumor uptake is comparable between 68Ga-FAPI and 18F-FDG, but lower background uptake in most normal organs results in equal or higher TBRs for 68Ga-FAPI. Thus, 68Ga-FAPI PET/CT may yield improved diagnostic information in various cancers and especially in tumor locations with high physiological 18F-FDG uptake.Open Access funding by Projekt DEAL.http://link.springer.com/journal/259am2022Nuclear Medicin

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT

Purpose!#!One therapy option for prostate cancer patients with bone metastases is the use of [!##!Methods!#!Multiple blood samples from nine prostate cancer patients were collected before and after administration of [!##!Results!#!The absorbed doses to the blood were less than 6 mGy up to 4 h after administration and maximally 16 mGy in total. Up to 4 h after administration, the α-track frequency was significantly increased relative to baseline and correlated with the absorbed dose to the blood in the dose range < 3 mGy. In most of the late samples (24 h - 4 weeks after administration), the α-track frequency remained elevated.!##!Conclusion!#!The γ-H2AX+53BP1 assay is a potent method for detection of α-particle-induced DNA damages during treatment with or after accidental incorporation of radionuclides even at low absorbed doses. It may serve as a biomarker discriminating α- from β-emitters based on damage geometry

M84/4 raw data of EM710 multibeam echosounder (bathymetry & beam time series)

Bathymetry data was acquired during R/V METEOR cruise M84/4 at the Galician Shelf off Northwest Spain in the Northeast Atlantic between 01.05.2011 and 28.05.2011. The main objectives of the cruise were the investigation of sediment transport processes from shallow to deep waters, understanding sediment dynamics, analysis of material downslope processes and the reconstruction of modern and past environmental conditions. The cruise comprised seismic, sedimentological, magnetic, geochemical and palaeoceanographic methods. Extensive bathymetric mapping during M84/4 based on the multibeam echosounders (MBES) KONGSBERG EM710 and EM122 provided the basis for sediment coring and additional investigations. Hydroacoustic data revealed the diverse morphology in the study area, driven by both sedimentary and tectonic processes, including contouritic deposits, slope gullies, canyon/channel systems, ridges and seamounts. The sub-bottom profiler PARASOUND, multichannel seismics, ADCP, several coring devices and the electromagnetic profiler MARUM-NERIDIS III complemented the research programme of the cruise. CI Citation: Paul Wintersteller ([email protected]) as responsible party for bathymetry raw data ingest and approval. Description of the data source: During the M84/4 cruise, the hull-mounted KONGSBERG EM710 multibeam echosounder (MBES) was utilized to perform bathymetric mapping of high resolution in water depths of 3 m to – theoretically – 2000 m. Best quality data is, however, achieved in water depths of less than 600 m, and in rough weather conditions less than 400 m. The EM710 operates at sonar frequencies of 70 to 100 kHz. Three sectors divide the transmit fan, where distinct frequencies or waveforms are transmitted sequentially. The swath width can reach 5.5 times the water depth. 256 beams with an acoustical 1°(TX)/1°(RX) footprint are formed for each ping. The transmit fan is electronically stabilized for roll, pitch and yaw. Combining phase and amplitude bottom detection algorithms allows achieving best possible accuracy. For further information, consult: https://epic.awi.de/id/eprint/26726/1/Kon2007b.pdf. The position and depth of the water column is estimated for each beam by using the detected two-way-travel time and the beam angle known for each beam and taking ray bending due to refraction in the water column by sound speed into account. During the M84/4 cruise, the EM710 was running in a 24-hour watch mode, in addition to the EM122 and the PARASOUND sub-bottom profiling system. Acquisition of EM710 data was reliable during the whole cruise; however, problems occurred during rough weather conditions, since the EM710 lost the bottom signal in depths of more than 400 m. Responsible person during this cruise / PI: Tilmann Schwenk ([email protected]) Chief Scientist: Till J. J. Hanebuth ([email protected]) CR: https://www.tib.eu/de/suchen/id/awi%3Adoi~10.2312%252Fcr_m84_4/ CSR: https://www.ldf.uni-hamburg.de/meteor/wochenberichte/wochenberichte-meteor/m84/m84-4-scr.pd